Abstract: Disclosed are methods for preventing the onset of autoimmune or inflammatory diseases in mammals using a pharmaceutical composition containing a pharmaceutically acceptable carrier and an effective amount of a thioether furan nitrone compound.

Abstract: Medical balloons and balloon preforms are made by methods which include the step of selectively removing material from the proximal and/or distal ends of a segment. In the case of a thermoplastic material characterized by one or more glass transition temperatures, the segment may optionally be maintained at a temperature below the glass transition temperature of the segment during the material removal step.

Abstract: Medical balloons and balloon preforms are made by methods which include the step of selectively removing material from the proximal and/or distal ends of a segment. In the case of a thermoplastic material characterized by one or more glass transition temperatures, the segment may optionally be maintained at a temperature below the glass transition temperature of the segment during the material removal step.

Abstract: Disclosed are methods for preventing and/or treating autoimmune and inflammatory diseases in mammals using a pharmaceutical composition containing a pharmaceutically acceptable carrier and an effective amount of a thiether furan nitrone compound.

Abstract: Disclosed are methods for treating a patient with an acute central nervous system or cardiovascular disorder or a neurodegenerative, autoimmune or inflammatory disease using a pharmaceutical composition containing a pharmaceutically acceptable carrier and an effective amount of a furan nitrone compound.

Abstract: Disclosed are novel .alpha.-aryl-N-alkylnitrone compounds and pharmaceutical compositions containing such compounds. The disclosed compositions are useful as therapeutics for preventing and/or treating neurodegenerative, autoimmune and inflammatory conditions in mammals and as analytical reagents for detecting free radicals.

Abstract: Disclosed are processes for preparing furan nitrone compounds using a furan carbonyl compound and a hydroxylamine compound.

Abstract: The present invention is directed to a vaginal insert for delivering an agent to a urogenital tract in a patient. The patient has a vagina, and the vagina has a vaginal wall. The vaginal insert comprises a base member sized to fit within the vagina, the base member defines a chamber and a port in fluid communication with the chamber. A membrane is operatively connected to the base member. The membrane defines a reservoir and a pore. The reservoir is in fluid communication with the port. The membrane is sized so that the vaginal wall will exert pressure against the membrane when fluid is in the reservoir, thereby forcing some of the fluid to flow through the pore and to tissue of the urogenital tract.

Abstract: Disclosed are novel thiophene nitrone compounds and pharmaceutical compositions containing such compounds. The disclosed compositions are useful as therapeutics for preventing and/or treating neurodegenerative, autoimmune and inflammatory conditions in mammals and as analytical reagents for detecting free radicals.

Abstract: Disclosed are novel thioether furan nitrone compounds and pharmaceutical compositions containing such compounds. The disclosed compositions are useful as therapeutics for preventing and/or treating neurodegenerative, autoimmune and inflammatory conditions in mammals and as analytical reagents for detecting free radicals.

Abstract: Disclosed are furansulfonic acid derivatives and pharmaceutical compositions containing such derivatives. The disclosed compositions are useful for preventing and/or treating neurodegenerative, autoimmune and inflammatory conditions in mammals.

Abstract: A vaginal insert and method for delivering an agent to a urogenital tract in a patient, the patient having a vagina, the vagina having anterior and posterior walls. The vaginal insert comprises a main portion and first and second portions operably connected to the main portion. The first and second portions each have an end projecting outward from the main portion, at least one of the projecting ends has means for containing the agent. The projecting ends of the first and second portions are configured to engage the anterior vaginal wall while the main portion engages the posterior vaginal wall, thereby positioning the projecting end of the first portion proximal to one side of the urogenital tract and positioning the projecting end of the second portion proximal to an opposite side of the urogenital tract.

Abstract: Disclosed are furan nitrone compounds and pharmaceutical compositions containing such compounds. The disclosed compounds are useful as analytical reagents for detecting free radicals and as therapeutics for treating a wide variety of medical dysfunctions and diseases.

Abstract: A vaginal insert for delivering an agent to a urogenital tract in a patient. The patient has a vagina, and the vagina has an anterior wall. The vaginal insert comprises a member sized to fit within the vagina. The member has a surface defining a channel configured to engage the anterior vaginal wall and receive tissue proximal to the urethra. The member defines a chamber for retaining a supply of the agent and a plurality of delivery ports. At least some of the delivery ports are located along the channel. The plurality of delivery ports are in fluid communication with the chamber. The vaginal insert also comprises first and second electrodes. The first electrode is operably connected to the member. The first and second electrodes configured to be operably connected to a power source so that an electrical current can pass between the first and second electrodes and through tissue proximal the urethra.

Abstract: Spin trapping compositions in general have now been discovered to be effective in treating a variety of disorders, including disorders such as those arising from ischemia, infection, inflammation, exposure to radiation or cytotoxic compounds, not just of the central and peripheral nervous systems but of peripheral organ disease having a wide variety of etiologies. In the preferred embodiment, the compositions for treating tissue damage from ischemia (DMPO include 5,5-dimethyl pyrroline N-oxide (DMPO), and spin-trapping derivatives thereof, in a suitable pharmaceutical carrier for intravenous, oral, topical, or nasal/pulmonary administration. Many different disorders can be treated using these compounds, including diseases or disorders of the central and peripheral nervous systems, and disorders arising from ischemia, infection, inflammation, oxidation from exposure to radiation or cytotoxic compounds, as well as due to naturally occurring processes such as aging.

Abstract: Novel spin traps comprising 2-trifluoromethyl-1-DMPO or derivatives thereof have now been found. An effective synthesis method for these spin traps is also disclosed.